Haitong International: Initiates coverage on SCIENTECH with an "Outperform" rating and a target price of HKD 28.94
I'm PortAI, I can summarize articles.
Haitong International initiates coverage on SCIENTECH with an "Outperform" rating and a target price of HKD 28.94. It is expected that the CAGR of the cardiac valve intervention market from 2021 to 2025 will reach 69.8%. The company's revenue for the first half of 2025 is projected to be RMB 330 million, a year-on-year increase of 32.4%; net profit attributable to the parent company is expected to be RMB 182 million, a year-on-year increase of 29.8%. SCIENTECH is a leader in the field of congenital heart disease intervention devices, and its biodegradable products reduce complications, providing significant clinical advantages
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments